| Parkinson's disease LV Kalia, AE Lang Lancet 386 (9996), 896-912, 2015 | 5535 | 2015 |
| Src kinases: a hub for NMDA receptor regulation MW Salter, LV Kalia Nature Reviews Neuroscience 5 (4), 317-328, 2004 | 933 | 2004 |
| NMDA receptors in clinical neurology: excitatory times ahead LV Kalia, SK Kalia, MW Salter The Lancet Neurology 7 (8), 742-755, 2008 | 533 | 2008 |
| Glycine binding primes NMDA receptor internalization Y Nong, YQ Huang, W Ju, LV Kalia, G Ahmadian, YT Wang, MW Salter Nature 422 (6929), 302-307, 2003 | 511 | 2003 |
| α‐Synuclein oligomers and clinical implications for Parkinson disease LV Kalia, SK Kalia, PJ McLean, AM Lozano, AE Lang Annals of neurology 73 (2), 155-169, 2013 | 387 | 2013 |
| Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease A Beilina, IN Rudenko, A Kaganovich, L Civiero, H Chau, SK Kalia, ... Proceedings of the National Academy of Sciences 111 (7), 2626-2631, 2014 | 380 | 2014 |
| Clinical Correlations With Lewy Body Pathology in LRRK2-Related Parkinson Disease LV Kalia, AE Lang, LN Hazrati, S Fujioka, ZK Wszolek, DW Dickson, ... JAMA neurology 72 (1), 100-105, 2015 | 323 | 2015 |
| Clinical correlations with lewy body pathology in LRRK2-related Parkinson's disease L Kalia, A Lang, L Hazrati, S Fujioka, Z Wszolek, D Dickson, O Ross, ... MOVEMENT DISORDERS 28, S405-S405, 2013 | 323 | 2013 |
| Severity of chronic pain and its relationship to quality of life in multiple sclerosis LV Kalia, PW OConnor Multiple Sclerosis 11 (3), 322-327, 2005 | 283 | 2005 |
| Disease‐modifying strategies for Parkinson's disease LV Kalia, SK Kalia, AE Lang Movement Disorders 30 (11), 1442-1450, 2015 | 279 | 2015 |
| Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD LV Kalia, AE Lang Nature Reviews Neurology, 2016 | 239 | 2016 |
| Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation KA Pelkey, R Askalan, S Paul, LV Kalia, TH Nguyen, GM Pitcher, ... Neuron 34 (1), 127-138, 2002 | 229 | 2002 |
| Animal models of [alpha]-synucleinopathy for Parkinson disease drug development JB Koprich, LV Kalia, JM Brotchie Nature Reviews Neuroscience 18 (9), 515-529, 2017 | 223 | 2017 |
| Neto1 is a novel CUB-domain NMDA receptor–interacting protein required for synaptic plasticity and learning D Ng, GM Pitcher, RK Szilard, A Sertié, M Kanisek, SJ Clapcote, T Lipina, ... PLoS Biol 7 (2), e1000041, 2009 | 207 | 2009 |
| Pathogenesis-targeted, disease-modifying therapies in Parkinson disease A AlDakheel, LV Kalia, AE Lang Neurotherapeutics 11 (1), 6-23, 2014 | 205 | 2014 |
| Src in synaptic transmission and plasticity LV Kalia, JR Gingrich, MW Salter Oncogene 23 (48), 8007-8016, 2004 | 205 | 2004 |
| Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors GM Pitcher, LV Kalia, D Ng, NM Goodfellow, KT Yee, EK Lambe, ... Nature medicine 17 (4), 470-478, 2011 | 183 | 2011 |
| α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era NP Visanji, JM Brotchie, LV Kalia, JB Koprich, A Tandon, JC Watts, ... Trends in Neurosciences 39 (11), 750-762, 2016 | 168 | 2016 |
| Ubiquitinylation of α-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5) LV Kalia, SK Kalia, H Chau, AM Lozano, BT Hyman, PJ McLean PloS one 6 (2), e14695, 2011 | 161 | 2011 |
| Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials LV Kalia, JM Brotchie, SH Fox Movement Disorders 28 (2), 131-144, 2013 | 144 | 2013 |
